跳至主要内容
临床试验/NCT00283595
NCT00283595已完成2 期

Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa

Massachusetts General Hospital1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
21
试验地点
1
主要终点
Bone Metabolism

研究概览

简要总结

Decreased bone strength is a serious medical problem present in many women with Anorexia Nervosa, or disordered eating. Women with weaker bones are more likely to suffer broken bones than women with normal bone strength.

We are investigating whether a hormone that is naturally produced by the human body, called growth hormone, can help strengthen the bones of women with this type of disordered eating.

详细描述

  • Twelve week study
  • Eight visits, six of which can be conducted at your home physician's office
  • Two bone density scans
  • Hormonal and nutritional evaluations

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
14 Years 至 45 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • women between 14 to 45 years with anorexia nervosa

排除标准

  • pregnancy
  • previous history of malignancy.
  • oral contraceptive pills or other hormones within last 8 - 12 weeks
  • medications known to affect bone within last 12 weeks
  • fracture within last 6 months

研究组 & 干预措施

1

Active Comparator

Treatment with rHGH

干预措施: Recombinant Human Growth Hormone (Drug)

2

Placebo Comparator

Treatment with Placebo

干预措施: Placebo for Recombinant Human Growth Hormone (Drug)

结局指标

主要结局

Bone Metabolism

时间窗: Baseline, 12 weeks

Change in the marker of bone formation, N-terminal pro peptide of type 1 procollagen (P1NP) levels, between baseline and 12 weeks

次要结局

  • IGF-1 Level(Baseline, 12 Weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Karen Klahr Miller, MD

Chief, Neuroendocrine Unit

Massachusetts General Hospital

研究点 (1)

Loading locations...

相似试验